This study is investigating if spironolactone, a medication already known to help with fluid retention, can also improve blood vessel function and reduce inflammation in people with pulmonary arterial hypertension (PAH). PAH is a rare condition where there is high blood pressure in the lungs. Researchers believe that inflammation plays a role in worsening PAH, and spironolactone has properties that might help. You may be able to join if you are between 18 and 100 years old and have Group 1 PAH, either not on medication or on stable medication for at least four weeks. The study will compare spironolactone to a placebo (an inactive pill) to see if spironolactone improves how far participants can walk in six minutes. The current status of this study is unclear, and it plans to enroll 70 participants.

Study design

This is an interventional study comparing spironolactone to a placebo in 70 participants. It is not specified if participants or researchers will know which treatment is being given.

What's involved

You would take either spironolactone or a placebo daily, starting with a lower dose and potentially increasing it after 7-9 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at 6 months, suggesting follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.